RVMD stock news

RVMD stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-23 16:35:00 UTC#507949updateconfirmednews

Tango Therapeutics shares drop 14% as vopimetostat pancreatic cancer study shows dose-limiting toxicities

dow_jonesimportance 0.60trust 0.80Tango Therapeutics, Inc. -0.60Revolution Medicines, Inc. +0.10vopimetostat -0.40+1 entities

2026-10-23 11:31:31 UTC#506239newconfirmednews

Revolution Medicines reports Rasonque improves survival across pancreatic cancer patient subgroups

reutersimportance 0.50trust 0.90Revolution Medicines, Inc. +0.60Rasonque +0.60

2026-10-21 15:21:00 UTC#494069newconfirmednews

TD Cowen sets $250.00 price target on Revolution Medicines (RVMD)

dow_jonesimportance 0.30trust 0.70Revolution Medicines, Inc. +0.40TD Cowen 0

2026-10-19 13:26:58 UTC#480837newconfirmednews

Truist Securities maintains Buy rating on Revolution Medicines, sets $241 price target

tradingviewimportance 0.40trust 0.60Revolution Medicines, Inc. +0.50Truist Securities, Inc. 0daraxonrasib +0.50

2026-10-15 22:38:00 UTC#468869newconfirmednews

Needham maintains $275.00 price target on Revolution Medicines (RVMD)

dow_jonesimportance 0.30trust 0.70Revolution Medicines, Inc. 0Needham & Company, LLC 0

2026-10-15 17:24:39 UTC#467554duplicatereportednews

Revolution Medicines signals intent for solo European commercial launch of Rasonque, Reuters reports

reutersimportance 0.30trust 0.90Revolution Medicines, Inc. +0.30

2026-10-15 17:22:18 UTC#467479updateconfirmednews

Revolution Medicines signals intent for solo European commercial launch of pancreatic cancer drug Rasonque

reutersimportance 0.50trust 0.80Revolution Medicines, Inc. +0.50Rasonque +0.60European Medicines Agency +0.20+2 entities

2026-10-15 15:58:00 UTC#466989duplicateconfirmednews

Revolution Medicines' pancreatic cancer drug Rasonque receives positive CHMP opinion for EU approval

dow_jonesimportance 0.30trust 0.80Revolution Medicines, Inc. +0.50Rasonque +0.50European Medicines Agency +0.30+2 entities

2026-10-15 15:02:05 UTC#466657duplicateconfirmednews

Revolution Medicines pancreatic cancer drug receives positive EU advisory panel opinion

bloombergimportance 0.30trust 0.90Revolution Medicines, Inc. +0.60European Medicines Agency +0.50

2026-10-15 14:43:57 UTC#466591duplicateconfirmednews

Revolution Medicines' Rasonque receives positive CHMP opinion for EU approval

seeking alphaimportance 0.30trust 0.70Revolution Medicines, Inc. +0.60Rasonque +0.60Committee for Medicinal Products for Human Use +0.60

2026-10-15 14:00:55 UTC#466311duplicateconfirmednews

EMA committee recommends EU approval for Revolution Medicines' pancreatic cancer drug Rasonque

reutersimportance 0.40trust 0.90European Medicines Agency 0Revolution Medicines, Inc. +0.60Rasonque +0.60

2026-10-15 13:49:44 UTC#466287duplicateconfirmednews

EMA recommends approval of Revolution Medicines' pancreatic cancer drug

reutersimportance 0.30trust 0.90European Medicines Agency 0Revolution Medicines, Inc. +0.70

2026-10-15 13:47:40 UTC#466248newconfirmednews

EMA recommends EU approval for Revolution Medicines' pancreatic cancer drug Rasonque

reutersimportance 0.65trust 0.90European Medicines Agency 0Revolution Medicines, Inc. +0.70Rasonque +0.70

2026-10-14 13:40:57 UTC#459457newconfirmednews

RBC Capital maintains Outperform rating on Revolution Medicines, sets $260 price target

tradingviewimportance 0.40trust 0.70Revolution Medicines, Inc. +0.40RBC Capital Markets, LLC +0.40daraxonrasib +0.40

2026-10-08 15:04:00 UTC#433360newconfirmednews

RBC Capital maintains Outperform on Revolution Medicines, raises price target to $259 from $251

dow_jonesimportance 0.30trust 0.70Revolution Medicines, Inc. +0.30RBC Capital Markets, LLC +0.30

2026-10-07 17:17:00 UTC#427265newconfirmednews

Truist Securities maintains Buy rating on Revolution Medicines, raises price target to $240 from $239

dow_jonesimportance 0.30trust 0.70Revolution Medicines, Inc. +0.30Truist Securities, Inc. 0

2026-09-28 17:05:00 UTC#379216newconfirmednews

Brookline Capital initiates coverage on Revolution Medicines (RVMD) with $318.00 price target

dow_jonesimportance 0.30trust 0.60Revolution Medicines, Inc. +0.30Brookline Capital Markets +0.30

2026-09-28 12:00:00 UTC#377297newconfirmednews

Revolution Medicines NDA for Daraxonrasib Accepted; KRAS Market Projected to Reach $7.85B by 2034

tradingviewimportance 0.40trust 0.50Revolution Medicines, Inc. +0.50Oncolytics Biotech Inc. +0.30Eli Lilly and Company +0.20+2 entities

2026-09-14 21:01:00 UTC#310134duplicateconfirmednews

Revolution Medicines Receives FDA Breakthrough Designation for Rasonque in Pancreatic Cancer Treatment

dow_jonesimportance 0.30trust 0.90Revolution Medicines, Inc. +0.50Food and Drug Administration +0.50Rasonque +0.50

2026-09-14 20:46:00 UTC#310054newconfirmednews

Revolution Medicines Rasonque Receives FDA Breakthrough Designation for Metastatic Pancreatic Cancer

dow_jonesimportance 0.50trust 0.80Revolution Medicines, Inc. +0.60Food and Drug Administration +0.40Rasonque +0.60+1 entities